Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

BACKGROUND: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O(6)-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin, Herrlinger, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007398/
https://ncbi.nlm.nih.gov/pubmed/29121274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados